Bloomberg
Establishing a Drug Pricing Strategy
June 6, 2024
An effective drug pricing strategy requires sustained corporate planning to understand and establish fair pricing in each market where a product is or will be commercialized. This strategy necessarily must include early planning at the development stage, close monitoring of legislative and regulatory pricing reforms in key markets, cross-functional and cross-jurisdictional collaboration across multiple disciplines within an organization, and sensitivity to political sentiment surrounding drug prices. The following checklist outlines high level action items, structural considerations, and substantive issues for pharmaceutical companies and their investors to consider to establish a thoughtful, holistic, and resilient drug pricing strategy for their development programs.
Contacts
Capabilities
Suggested News & Insights
Most-Favored-Nation Drug Pricing Policy: Executive Actions, Manufacturer Agreements, and Growing Congressional ScrutinyApril 22, 2026Medical Products Market Access: Favorable Advisory Opinion Reaffirms Discounting FlexibilitiesJanuary 21, 2026U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025CMS Announces Voluntary Most-Favored-Nation Pricing in Medicaid Through the GENEROUS ModelNovember 11, 2025Rare Disease and Specialty Product Manufacturers: Distribution Model ConsiderationsSeptember 16, 2025U.S. DOJ Announces Renewal of FCA Working GroupJuly 7, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory

